AFRY enables Vistin Pharma to double the production capacity of diabetes medicine
As partner for five years of Vistin Pharma, AFRY has been entrusted to carry out a turn key project and build a plant with the purpose of doubling the production capacity of the diabetes medicine Metformin for diabetes type 2.Diabetes type 2 is the most common diabetes disease and a growing endemic disease across the world. It usually develops in adulthood and means that the body still produces insulin, but just not enough. The International Diabetes Federation, IDF, estimates that by 2040, 642 million people will have diabetes. In 2015, that figure was 415 million. This demands for